Can an Apheresis Therapy become an Effective Method for Anti-Aging Medicine?

100 During last 30 years, apheresis technologies had helped to treat many diseases by removing pathological macromolecules or pathological cells from patient’s blood. They included the cryofiltration to remove cryogel and the thermofiltration to remove LDL cholesterol. Unfortunately during these 30 years, developments of new apheresis technologies were not actively pursued by apheresis practitioners in the world including our group. Some diseases once treated by apheresis procedures were also shrank substantially. However, we believed that apheresis therapy had many possibilities to treat the major disease categories including heart diseases, diabetes mellitus and cancer. Even aging process might be able to be prevented by apheresis therapy. In this paper, we should go over current membrane apheresis technologies and should introduce our concept of “Juzo” as an Anti-Aging artificial organ which was presented in 1995. Then we should introduce the new types of the 2nd generation apheresis technologies by referencing recent papers which supported our study directions. The new technologies included in this paper were the cryoaggregate filtration to remove pathological globulin molecules for the treatment of cardiomyopathic diseases, cryoreactive albumin removal apheresis (CRARA) for the treatment and for the prevention of diabetic complications of diabetic patients by removing pathological albumin and bioincompatible apheresis system for cancer treatment. In conclusion, apheresis therapies could remove pathological molecules accumulated excessively in the aging living body. The return to the normal levels of these molecules might be an effective interventional method as an Anti-Aging medical therapy.

[1]  H. Miyamoto,et al.  Molecular surgery for the treatment of malignant tumors: bioincompatible material apheresis for cancer therapy? , 2011, Artificial organs.

[2]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[3]  B. Friguet,et al.  Oxidized mitochondrial protein degradation and repair in aging and oxidative stress. , 2010, Antioxidants & redox signaling.

[4]  L. Rybicki,et al.  Apheresis Technologies and Clinical Applications: The 2007 International Apheresis Registry , 2010, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[5]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[6]  M. Emoto,et al.  Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. , 2008, Life sciences.

[7]  E. Bonifacio,et al.  Heparin-induced Extracorporal LDL Precipitation (H.E.L.P) in Diabetic Foot Syndrome – Preventive and Regenerative Potential? , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  H. Makino,et al.  Glycated albumin levels predict long‐term survival in diabetic patients undergoing haemodialysis , 2008, Nephrology.

[9]  S. Sela,et al.  Heparin Cryoprecipitation Reduces Plasma Levels of Non-Traditional Risk Factors for Atherosclerosis in vitro , 2008, Blood Purification.

[10]  Qi Zhang,et al.  Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus. , 2007, Clinical biochemistry.

[11]  B. Friguet.  Oxidized protein degradation and repair in ageing and oxidative stress , 2006, FEBS letters.

[12]  T. Squier,et al.  Oxidative stress and protein aggregation during biological aging , 2001, Experimental Gerontology.

[13]  P. Malchesky,et al.  Therapeutic cryogel removal in autoimmune disease: what is cryogel. 1982. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[14]  P. Malchesky,et al.  Therapeutic Membrane Plasmapheresis , 2000 .

[15]  T. Agishi,et al.  Double filtration plasmapheresis. , 2000, Transactions - American Society for Artificial Internal Organs.

[16]  E. Shacter.  QUANTIFICATION AND SIGNIFICANCE OF PROTEIN OXIDATION IN BIOLOGICAL SAMPLES* , 2000, Drug metabolism reviews.

[17]  M. Jadoul,et al.  Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. , 1998, Journal of the American Society of Nephrology : JASN.

[18]  Y. Nosé,et al.  Membrane apheresis technology: historical perspective and new trends toward bioincompatible systems. , 1997, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[19]  Y. Nosé.  5th WAA Congress therapeutic artificial organs, 10 years after. , 1995, Artificial organs.

[20]  D. Seidel,et al.  LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. , 1993, Transfusion science.

[21]  P. Malchesky,et al.  Clinical thermofiltration: initial application. , 1985, Artificial organs.

[22]  Y. Nosé.  Therapeutic artificial organs: future perspectives. , 1985, Artificial Organs.

[23]  M. Blumenstein,et al.  On-line separation of macromolecules by membrane filtration with cryogelation. , 1980, Artificial organs.

[24]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[25]  H. Tsuda,et al.  Effect of Double Filtration Plasmapheresis (DFPP) in Male Patients with Borderline Hyper-LDL-cholesterolemia : Lipid Removal and Inflammation Suppression , 2009 .

[26]  Qi Zhang,et al.  Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes , 2006 .

[27]  P. Malchesky,et al.  Cryopheresis: immunochemical modulation and clinical response in autoimmune disease. , 1982, Transactions - American Society for Artificial Internal Organs.

[28]  Smith Jw,et al.  Clinical hepatic support by on-line plasma treatment with multiple sorbents - evaluation of system performance. , 1980, Transactions - American Society for Artificial Internal Organs.

[29]  M. Sugiura,et al.  TREATMENT OF INTRACTABLE ASCITES BY CONTINUOUS REINFUSION OF THE STERILIZED, CELL‐FREE AND CONCENTRATED ASCITIC FLUID , 1977, Transactions - American Society for Artificial Internal Organs.